Not all people with CLL require therapy. In spite of all latest advances, the iwCLL continue to suggests watchful observation for patients with asymptomatic disease.86 This advice is predicated on at the least two randomized trials evaluating observation to either chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).Deep, f